Rensselaer, NY and Archamps, France — January 20, 2026 - Taconic Biosciences, Inc., a global leader in genetically engineered rodent models (GEMs) and humanized immune system (HIS) mouse models, today announced the acquisition of TransCure bioServices SAS, a leading provider of preclinical research services utilizing HIS mouse models. This acquisition enables Taconic to offer a unified global platform delivering seamless end-to-end solutions for their customers – providing humanized models, precise cohort generation, and in vivo studies. Researchers will benefit from the integration of Taconic’s global production infrastructure, validated GEMs, HIS and humanized liver mouse models, and rigorous genetic and health quality systems with TransCure’s deep expertise in disease-specific translational pharmacology, cutting-edge flow cytometry, immune profiling, immunohistochemistry, and imaging solutions.
“This acquisition establishes a fully integrated translational research engine giving researchers a more predictive, efficient, and reliable alternative than fragmented multi-vendor workflows,” said Mike Garrett, CEO of Taconic Biosciences. “Taconic’s world-class animal models combined with TransCure’s state-of-the-art preclinical services create a uniquely powerful platform for drug discovery and translational research, offering global customers a robust suite of preclinical solutions spanning model generation, humanization, engraftment, cohort customization, and advanced in vivo pharmacology.”
The acquisition further strengthens Taconic’s capabilities across oncology, immunology, infectious disease, inflammation, metabolic disease, and advanced modalities, providing researchers with the humanized systems essential for developing complex, mechanism-driven therapies. The combination expands both companies’ geographic footprint and enhances the breadth of proprietary models, expertise, and study capabilities available to global biotech and pharmaceutical innovators.
By preserving TransCure’s established brand and operational structure, both companies aim to ensure a seamless transition for employees, clients, and partners.
“Today marks an exciting new chapter for our team and our customers. Joining forces with Taconic enables us to expand our capabilities and deliver even greater value to researchers worldwide,” said Sebastien Tabruyn, CEO of TransCure. “We are proud to join a larger family, strengthening our commitment to innovation and ensuring our focus on delivering exceptional customer success remains stronger than ever.”
